

OVERVIEW

This Fall 2022, the European Society for Medical Oncology (ESMO) and Total Health Conferencing partner to expand access to oncology education in the U.S. with three hybrid medical education programs. With the support of ESMO, Total Health Conferencing will host an educational experience in **Philadelphia**, **PA on Saturday and Sunday**, **October 22-23**, **2022**.

The free conference will cover highlights from the ESMO Congress 2022, equipping healthcare providers with the latest strategies to improve clinical practice and treatment outcomes in cancer care. The relationship will allow for a broader, more community accessible, and rapid review style dissemination of the clinical updates and expertise.

Join the program in-person in Philadelphia, PA or virtually. Registration is free for all healthcare providers.

LEARNING OBJECTIVES

- Examine scientific advances that further enhance knowledge of cancer biology and pathogenesis
- Review recent and emerging data from key studies in clinical cancer research
- Evaluate the role of new diagnostic techniques and therapeutic approaches as applied to the care and management of people with cancer
- Implement clinical and scientific strategies designed to improve the quality of cancer care, as appropriate
- Effectively communicate with colleagues and with patients regarding advances in clinical oncology science
- Identify and utilize tools for cancer risk assessment and risk reduction based on the best available evidence

WHAT TO EXPECT

- Free registration for all healthcare providers
- Expert sessions that present the most clinically relevant data, research, and clinical strategies
- Enduring video content for watching at your leisure
- Networking with peers, colleagues, and medical professionals
- Access to the latest industry information and resources

For In-Person Only:

- Exclusive Networking Reception
- Catered Meals throughout the Weekend
- Great Prizes when you participate
- Health and safety guidelines and regulations

PROGRAM CHAIRS



Shayma Master Kazmi, MD, RPh Medical Oncologist/Hematologist Penn Medicine



Florian Lordick, MD, PhD ESMO Director of Education University of Leipzig, Germany

ACCREDIATION | 7.75 CREDITS

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



VEESSIONAL CONTI

Nurses (ANCC) Credit Designation Amedco LLC designates this activity for a maximum of 7.75 ANCC contact hours.

Physicians (ACCME) Credit Designation Amedco LLC designates this live activity for a maximum of 7.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 7.75 knowledge-based CPE contact hours.

American Board of Internal Medicine (ABIM) MOC Credit



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.



OCTOBER 22, 2022 | DAY 1 AGENDA

OCTOBER 22, 2022 DAY 1 AGENDA	
08:15 AM	Coffee and Exhibits
08:45 AM	Welcome and Opening Remarks
09:00 AM	Global Challenges in Comprehensive Genomic Profiling & Precision Oncology Dr. Shayma Kazmi Penn Medicine
09:20 AM	Management of Oligometastatic Prostate Cancer Dr. Jessica Wong Fox Chase Cancer Center
09:40 AM	Updates for Radiation in Prostate Cancer Dr. Steven Finkelstein Florida Cancer Specialists
10:00 AM	Breakfast and Exhibits
10:15 AM •	 Exploring a Treatment Option for Patients with Previously Treated Metastatic Small Cell Lung Cancer (SCLC) Dr. Janakiraman Subramanian Inova Schar Cancer Institute
10:15 AM •	 Understanding Tivdak (tisotumab vedotin-tftv) Dr. Thomas Krivak Allegheny Health Network
11:00 AM	Break and Exhibits
11:20 AM	 Who Should I Test for Genetics Outside BRCA? Dr. Jennifer Klemp University of Kansas
11:40 AM	 Sex and Cancer Dr. Jennifer Reese Fox Chase Cancer Center
12:00 PM •	Diagnostics in Early BC—Who, Which Test, and When Dr. Payal Shah Penn Medicine Dr. Maysa M. Abu-Khalaf Jefferson Health
12:30 PM	Lunch and Exhibits
12:45 PM	A First-Line CDK4/6 Inhibitor Combination Therapy: Clinical Trial Evidence Complemented by a Real-World Effectiveness Evaluation Dr. Neil Iyengar Memorial Sloan Kettering Cancer Center
12:45 PM •	For Adult Patients With Locally Advanced or Metastatic EGFR+ Non-Small Cell Lung Cancer With Exon 20 Insertion Mutations Whose Disease has Progressed on or After Platinum-Based Chemotherapy Dr. David Waterhouse Dana-Farber Brigham Cancer at Milford Regional Medical Center
01:30 PM	Break and Exhibits
01:50 PM	Non-Cutaneous Melanoma Dr. Justine Cohen Penn Medicine
02:10 PM	Non-Melanoma Skin Cancers Dr. Jeffrey Farma Fox Chase Cancer Center
02:30 PM	 Artificial Intelligence and Oncology Care Dr. Arturo Loaiza-Bonilla Capital Health Cancer Center
02:50 PM	Break and Exhibits
03:05 PM •	 Consider TRODELVY® (sacituzumab govitecan-hziy) in 2L and Later mTNBC Dr. Jules Cohen Stony Brook Cancer Center
03:50 PM •	New Classifications and Staging in Breast Cancer Dr. Manisha Bahl Mass General
04:10 PM	 Antibody Drug Conjugates in Metastatic Breast Cancer Dr. Sramila Aithal Alliance Cancer Specialists
04:30 PM	Networking Reception - In Person Only
05:30 PM	Adjourn

OCTOBER 23, 2022 | DAY 2 AGENDA 08:15 AM **Coffee and Exhibits** Welcome and Opening Remarks 08:45 AM 09:00 AM Immunotherapy and Targeted Treatment for mNSCLC Dr. Neal Ready | Duke Health Updates in Small Cell Lung Cancer 09:20 AM Dr. Mahdi Taha | Florida Cancer Specialists 09:40 AM Treatment Strategies for Non-mNSCLC Dr. Patrick Forde | Johns Hopkins 10:00 AM **Breakfast and Exhibits** 10:15 AM A Combination Treatment for Patients with Advanced Renal Cell Carcinoma Dr. Michael Harrison | Duke Cancer Institute **Break and Exhibits** 11:00 AM 11:20 AM Young Patients with Multiple Myeloma and Complications Dr. Shonali Midha | Dana-Farber Cancer Institute How to Treat Early Relapses in Lymphoma Dr. Amanda Cashen | Washingston University 11:45 AM St. Louis Hematology Update: How Diagnostic Tools 12:10 PM Impact Therapy of Hematological Malignancies Dr. Onyee Chan | Moffitt Cancer Center 12:40 PM Lunch and Exhibits LONSURF® (trifluridine and tipiracil) 12:55 PM tablets: Oral chemotherapy for previously treated metastatic colorectal, gastric and gastroesophageal (GEJ) cancers Dr. Benjamin A. Weinberg | MedStar Georgetown University Hospital 12:55 PM **Treatment Options for Patients with** Resectable and Metastatic Non-Small Cell Lung Cancer Dr. David M Waterhouse \mid Dana-Farber/Brigham and Women's Cancer Center 01:40 PM CtDNA and MRD — How, When, and Who Dr. Kristen Ciombor | Vanderbilt 02:00 PM Updates in Upper GI Cancer Dr. Florian Lordick | University Cancer Center Leipzig, Germany 02:20 PM **Break and Exhibits** 02:40 PM A Treatment Option for Certain Patients With Advanced Esophageal Cancer Dr. Angela Tatiana Alistar | Atlantic Medical Group-Oncology GRAIL and Multi-Cancer Early Detection: 02:40 PM An Update from ESMO Dr. Eric Fung | GRAIL, LLC 03:25 PM Plenty of Choices in Rectal Cancer Dr. Robert Roses | Penn Medicine 03:45 PM Immunotherapy and Targeted Treatment for mCRC Dr. Dustin Deming | University of Wisconsin

04:05 PM

Adjourn

Agenda subject to change. All times are EST.

